Randomised phase II trial of Cediranib and Olaparib Maintenance in advanced/recurrent Cervical Cancer (COMICE)

Trial Profile

Randomised phase II trial of Cediranib and Olaparib Maintenance in advanced/recurrent Cervical Cancer (COMICE)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Cediranib (Primary) ; Olaparib (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms COMICE
  • Most Recent Events

    • 22 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top